A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6
- Author(s)
- Hughes, BGM; Guminski, A; Bowyer, S; Migden, MR; Schmults, CD; Khushalani, NI; Chang, ALS; Grob, JJ; Lewis, KD; Ansstas, G; Day, F; Ladwa, R; Stein, BN; Muñoz Couselo, E; Meier, F; Hauschild, A; Schadendorf, D; Basset-Seguin, N; Modi, B; Dalac-Rat, S; Dunn, LA; Flatz, L; Mortier, L; Guégan, S; Heinzerling, LM; Mehnert, JM; Trabelsi, S; Soria-Rivas, A; Stratigos, AJ; Ulrich, C; Wong, DJ; Beylot-Barry, M; Bossi, P; Bugés Sánchez, C; Chandra, S; Robert, C; Russell, JS; Silk, AW; Booth, J; Yoo, SY; Seebach, F; Lowy, I; Fury, MG; Rischin, D;
- Journal Title
- Journal of the American Academy of Dermatology
- Publication Type
- Online publication before print
- Abstract
- BACKGROUND: In the phase 2 EMPOWER-CSCC-1 study (NCT02760498), cemiplimab demonstrated antitumor activity against metastatic (mCSCC) and locally advanced cutaneous squamous cell carcinoma (laCSCC). OBJECTIVES: To report final analysis of weight-based cemiplimab in mCSCC and laCSCC (Groups 1 and 2), fixed-dose cemiplimab in mCSCC (Group 3), and primary analysis of fixed-dose cemiplimab in mCSCC/laCSCC (Group 6). METHODS: Patients received cemiplimab (3 mg/kg intravenously [IV] every 2 weeks [Groups 1 and 2]) or cemiplimab (350 mg IV [Groups 3 and 6]) every 3 weeks. The primary endpoint was objective response rate (ORR). Duration of response (DOR) and progression-free survival (PFS) are presented per protocol, according to post-hoc sensitivity analyses that only include the period of protocol-mandated imaging assessments. RESULTS: At 42.5 months, ORR for Groups 1-3 (n=193) was 47.2%, estimated 12-month DOR was 88.3%, and median PFS was 26.0 months. At 8.7 months, ORR for Group 6 (n=165 patients) was 44.8%; median DOR and median PFS were not reached. Serious treatment-emergent adverse event rates (grade ≥3) were Groups 1-3: 31.1% and Group 6: 34.5%. LIMITATIONS: Non-randomized study, non-survival primary endpoint. CONCLUSION: EMPOWER-CSCC-1 provides the largest prospective data on long-term efficacy and safety for anti-programmed cell death-1 therapy in advanced CSCC.
- Keywords
- advanced cutaneous squamous cell carcinoma; cemiplimab; clinical trials; fixed dose; immunotherapy; skin cancer; skin neoplasms
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1016/j.jaad.2024.06.108
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-01 03:15:14
Last Modified: 2024-10-01 05:06:17